BASKING RIDGE, N.J., Oct. 5 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer therapeutics, announced today that it will present at the BIO InvestorForum on Thursday, October 11, 2007 at 2:00 p.m. Pacific Time at the Palace Hotel in the Sea Cliff Room in San Francisco. Daniel Greenleaf, VioQuest's president and CEO, is scheduled to give an overview of the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )
The BioInvestor Forum is dedicated to public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in life sciences
The 4th Annual BIO InvestorForum will showcase to the investment community public and venture-stage growth companies as well as those poised to join the growth "watch list" in the coming year.
About VioQuest Pharmaceuticals
VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits activation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases (PTPases), SHP-1 and SHP-2, which has shown compelling clinical and biological activity in solid tumors and Xyfid(TM), a topical therapy which has shown early clinical promise in the treatment and prevention of chemo-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing several Phase II trials for VQD-002, Lenocta(TM) and Xyfid(TM) in the second half of 2007. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2007 for Lenocta(TM) for the treatment of leishmaniasis.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. In addition, this press release also includes forward-looking statements regarding the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of VioQuest's drug development product candidates. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
dan.greenleaf@vioquestpharm.combrian.lenz@vioquestpharm.comlisa.lindberg@vioquestpharm.com
CONTACT: Daniel Greenleaf, President and Chief Executive Officer,
+1-908-766-4400 ext. 115, dan.greenleaf@vioquestpharm.com, or Brian Lenz,
Chief Financial Officer, +1-908-766-4400 ext. 117,
brian.lenz@vioquestpharm.com, or Lisa Lindberg, Vice President of Investor
Relations and Corporate Communications, +1-908-766-4400 ext. 116,
lisa.lindberg@vioquestpharm.com, all of VioQuest Pharmaceuticals
Web site: http://www.vioquestpharm.com//
